Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $17.33
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month […]
More Stories
Tesco PLC Declares Dividend of GBX 4.25 (LON:TSCO)
Tesco PLC (LON:TSCO – Get Free Report) announced a dividend on Thursday, October 3rd, Upcoming.Co.Uk reports. Shareholders of record on...
The Detroit Legal News Company (OTCMKTS:DTRL) Announces $2.00 Quarterly Dividend
The Detroit Legal News Company (OTCMKTS:DTRL – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports....
JPMorgan Asia Growth & Income plc (LON:JAGI) to Issue Dividend of GBX 4.20
JPMorgan Asia Growth & Income plc (LON:JAGI – Get Free Report) declared a dividend on Tuesday, October 1st, Upcoming.Co.Uk reports....
Aquila Energy Efficiency Trust (LON:AEET) Announces Dividend Increase – GBX 6.14 Per Share
Aquila Energy Efficiency Trust (LON:AEET – Get Free Report) announced a dividend on Friday, September 27th, Upcoming.Co.Uk reports. Investors of...
Analysts Set CACI International Inc (NYSE:CACI) Target Price at $485.60
CACI International Inc (NYSE:CACI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven...
Corebridge Financial, Inc. (NYSE:CRBG) Receives Average Recommendation of “Moderate Buy” from Analysts
Corebridge Financial, Inc. (NYSE:CRBG – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve...